Prospective post marketing surveillance to evaluate the safety and efficacy of etanercept under usual care settings in patients with psoriatic arthritis (PsA) treated by dermatologists.

Trial Profile

Prospective post marketing surveillance to evaluate the safety and efficacy of etanercept under usual care settings in patients with psoriatic arthritis (PsA) treated by dermatologists.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2013 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top